Filing Flows › Cartesian Therapeutics (RNAC) › Q1 2025
Cartesian Therapeutics (RNAC) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Cartesian Therapeutics (RNAC) reported revenue of $1.1M for the first quarter 2025 (Q1 2025), -81% from a year earlier.
Cartesian Therapeutics, Q1 2025: revenue $1.1M (-81% year over year), net loss $17.7M, operating cash flow −$23.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | — | -81% |
| Operating profit | −$21.9M | — | — |
| Net earnings | −$17.7M | — | — |
| Operating cash flow | −$23.1M | — | — |
What changed
Revenue was $1.1M in Q1 2025, down 81% year over year.
Operating costs exceeded revenue by $21.9M, an operating margin of -1989.9%. Total costs grew 20% against a revenue fall of 81%. The fastest-growing cost line was Research & development (+51%). The quarter ended with a net loss of $17.7M. Non-operating items added $4.2M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$23.1M. Non-cash charges added back $600K of depreciation and $2.5M of share-based compensation. Working capital and other items used $8.5M. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$24.2M.
Questions
What was Cartesian Therapeutics' revenue in the first quarter 2025?
Cartesian Therapeutics (RNAC) reported revenue of $1.1M for the first quarter 2025 (Q1 2025), -81% from a year earlier.